7:37 AM
May 17, 2018
 |  BC Extra  |  Clinical News

Loxo gains on Phase I RET inhibitor data

Loxo Oncology Inc. (NASDAQ:LOXO) gained $28.03 (20%) to $167.53 Thursday after reporting response data from a Phase I trial of its ret proto-oncogene (RET) inhibitor LOXO-292 to treat RET-altered cancers. The data were released late Wednesday in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

In 32 evaluable patients with RET fusion-positive tumors, oral LOXO-292 led to an overall response rate (ORR) of 69%, including an ORR of 65% in 26 non-small cell lung cancer (NSCLC) patients and 83% in six papillary thyroid cancer patients. Additionally, 84% of patients had radiographic tumor reductions of 19-67%.

LOXO-292 also led to tumor reductions of 9-45%, including two partial responses, in 11 of 14 evaluable patients with RET-mutant medullary thyroid cancer (MTC).

Blueprint Medicines Corp. (NASDAQ:BPMC), which is developing RET inhibitor BLU-667, dipped $4.48 to $81.90 Thursday.

At April's American Association for Cancer Research meeting, Blueprint reported data from the Phase I ARROW trial showing that BLU-667 led to an ORR of 50% in 14 evaluable patients with with RET-altered NSCLC. Among 25 patients with RET-altered MTC, BLU-667 led to an ORR of 40% (see BioCentury Extra, April 16).

With Thursday's moves, Loxo added nearly $850 million in market cap, while Blueprint shed almost $200 million.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD